Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data

BACKGROUND: CT-P13 is an infliximab biosimilar that was granted market authorization in Switzerland in 2016. Despite the growing literature supporting the equivalence of CT-P13 compared with originator infliximab regarding the efficacy, safety, and immunogenicity and the undeniable cost-saving oppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Krstic, Marko, Devaud, Jean-Christophe, Marti, Joachim, Sadeghipour, Farshid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392673/
https://www.ncbi.nlm.nih.gov/pubmed/35590047
http://dx.doi.org/10.1007/s40801-022-00299-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392673/
https://www.ncbi.nlm.nih.gov/pubmed/35590047
http://dx.doi.org/10.1007/s40801-022-00299-2

Ejemplares similares